Drug Pipeline

KITE-363 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
2
Recruiting
1
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-04 NCT04989803
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell…		 Trial sites expanded: 18 -> 21 locations
Active Studies by Phase
Phase 1/2
1
Phase 1
2
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT04989803 Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell… Relapsed and/or Refractory B-cell Lymphoma Recruiting
Phase 1
NCT07304154 A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune… Chronic Inflammatory Demyelinating Polyneuropathy Recruiting
NCT07038447 A Study of KITE-363 in Participants With Refractory Autoimmune Diseases Systemic Lupus Erythematosus Enrolling by Invitation
Not specified
NCT05041309 Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies… Solid and Hematological Malignancies Enrolling by Invitation
Sponsors Running KITE-363 Trials
Kite, A Gilead Company (4)
Disease Areas
Lupus (SLE) (1) Scleroderma (1) Multiple Sclerosis (1) Myasthenia Gravis (1)
Get alerts when KITE-363 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free